Assertio Therapeutics, Inc. Aktie News

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the “Certificate of Amendment”) on December 19 to implement a one-for-fifteen reverse split of its issued and outstanding common stock (the “Reverse Split”). The Reverse Split will become effective ...

Assertio Holdings, Inc. ( ASRT ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Mark L. Reisenauer - CEO & Director Paul Schwichtenberg - Executive VP & Chief Transformation Officer Ajay Patel - Executive VP & CFO Conference Call Participants Daniel Santos Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Div...

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today reported financial results for the third quarter ended September 30, 2025. Mark Reisenauer, Chief Executive Officer, stated: “In the third quarter ...

Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill.

SAN FRANCISCO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.

SAN FRANCISCO, Sept. 21, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.

SAN FRANCISCO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.

PHILADELPHIA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”).